OPTINOSE INC (OPTN)       3.6  +0.07 (+1.98%)

3.6  +0.07 (+1.98%)

US68404V1008 - Common Stock

OPTINOSE INC3.6

NASDAQ:OPTN (10/4/2022, 10:21:08 AM)+0.07 (+1.98%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Pharmaceuticals
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-11 2022-08-11/bmo Earnings (Next) 11-14 2022-11-14
Ins Owners 1.99% Inst Owners 39.48%
Market Cap 299.80M Shares 83.28M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 82
IPO 10-13 2017-10-13

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

OPTN Daily chart

Company Profile

OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 189 full-time employees. The company went IPO on 2017-10-13. The firm's first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing the Company's Exhalation Delivery System (EDS), which delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.

Company Info

OPTINOSE INC

1020 Stony Hill Rd Ste 300

Yardley PENNSYLVANIA 19067

P: 12673643500.0

CEO: Peter K. Miller

Employees: 189

Website: https://www.optinose.com/

OPTN News

News Imagea month ago - Optinose, Inc.Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting

ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical Rhinology...

News Image2 months ago - Optinose, Inc.Optinose Reports Second Quarter 2022 Financial Results and Operational Updates

Company reports second quarter XHANCE net revenue of $20.6 million increased 12% compared to second quarter 2021 Company plans to submit an sNDA for...

News Image2 months ago - Optinose, Inc.Optinose Announces Reporting Date for Second Quarter 2022 Financial Results

Conference Call and Webcast to be held August 11, 2022, at 8:00 a.m. Eastern Time...

News Image3 months ago - OptiNose, Inc.Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis ...

News Image3 months ago - OptiNose, Inc.Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic...

News Image4 months ago - OptiNose, Inc.Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients ...

OPTN Twits

Here you can normally see the latest stock twits on OPTN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example